Company / SG&A per Share
Amylyx Pharmaceuticals, Inc. SG&A per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$0.57
FY2025
5-year range
$0.57 / $18.11
FY2021-FY2025
Trend
-65.6%
vs FY2024
Sector context
#156 of 210
Health Care
What the data says
At $0.57, Amylyx Pharmaceuticals, Inc.'s sg&a per share ranks #55 of 210 in the Health Care sector. SG&A per Share has declined for 3 consecutive years, from $18.11 in FY2022 to $0.57 in FY2025.
Based on SEC 10-K filings.
0.57 in FY2025 with a 3-year CAGR of -68.4%.
Improved from $2.78 to $0.57 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -68.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#55 of 210 in Health CareTop 26% of 210This company $0.57 Sector average $40.75
▼
-98.6% below sector average
Key checks
Key Insights
- Amylyx Pharmaceuticals, Inc.'s sg&a per share has declined for 3 consecutive years.
- In FY2025, sg&a per share decreased 65.6% year-over-year.
- Ranks #156 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2022.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.57 | -65.6% |
| FY2024 | $1.67 | -40.1% |
| FY2023 | $2.78 | -84.6% |
| FY2022 | $18.11 | +206.3% |
| FY2021 | $5.91 | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026